Filing Details

Accession Number:
0001209191-20-012454
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-02-25 16:21:42
Reporting Period:
2020-02-25
Accepted Time:
2020-02-25 16:21:42
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1124105 Catalyst Biosciences Inc. CBIO Pharmaceutical Preparations (2834) 562020050
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1262327 Augustine Lawlor C/o Catalyst Biosciences, Inc.
611 Gateway Blvd., Suite 710
South San Francisco CA 94080
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-02-25 69,401 $6.10 0 No 4 S Indirect By HealthCare Ventures VIII, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By HealthCare Ventures VIII, L.P.
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 15,608 Direct
Footnotes
  1. Represents the weighted average sales price per share. The shares sold at prices ranging from $6.10 to $6.22 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  2. HealthCare Ventures VIII, L.P. ("HCVVIII") is the registered owner of the securities. The Reporting Person is a managing director of HealthCare Partners VIII, LLC ("HCPVIII LLC"), the General Partner of HealthCare Partners VIII, L.P. ("HCPVIII"). HCPVIII is the General Partner of HCVVIII. The Reporting Person shares voting and investment power over the shares held by HCVVIII with each of Christopher Mirabelli, James Cavanaugh, John Littlechild and Harold Werner as managing directors of HCPVIII LLC. The Reporting Person disclaims beneficial ownership of those securities in which he does not have a pecuniary interest and this report shall not be deemed an admission that he is the beneficial owner of these securities for purposes of Section 16, except to the extent of his pecuniary interest therein.